Deals In Depth: April 2013
Roche is optioning Isis’ Huntington’s disease antisense candidates in a deal worth $282 million and Thermo Fisher paid just over $15 billion for Life Technologies. Biopharma financing was up 23% to $1.2 billion, device fundraising down 35% to $338 million.
You may also be interested in...
China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.
The J&J company holding the firm’s liabilities relating to talc litigation, which declared bankruptcy in 2021 shortly after its formation, had its Chapter 11 petition denied by the Third Circuit on 30 January. Attorneys weigh in on the implications for J&J and wider industry.
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.